Limitations of Anti-Angiogenic Treatment of Tumors

Clinical trials using anti-vascular endothelial growth factor /(VEGF) molecules induce a modest improvement in overall survival, measurable in weeks to just a few months, and tumors respond differently to these agents. In this review article, we have exposed some tumor characteristics and processes...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribatti, Domenico, Annese, Tiziana, Ruggieri, Simona, Tamma, Roberto, Crivellato, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Review article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529826/
https://www.ncbi.nlm.nih.gov/pubmed/31121490
http://dx.doi.org/10.1016/j.tranon.2019.04.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529826/
https://www.ncbi.nlm.nih.gov/pubmed/31121490
http://dx.doi.org/10.1016/j.tranon.2019.04.022

Ejemplares similares